Advanced disease progression occurred less often with vutrisiran than placebo in both the overall population (8.0% vs 10.7%) and monotherapy subgroup (8.2% vs 11.1%). Transition to NYHA class IV was ...
19h
CPR goes high-tech: Transesophageal echocardiography turns blind compressions into precision hits
By conducting the world's first randomized clinical trial, researchers have demonstrated that while overall survival rates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results